Table 1.
Pre-HCT demographic and clinical characteristics of study cohort (n = 979), stratified according to disease status at diagnosis (de novo vs. therapy-related vs. after antecedent hematologic disorder [AHD]).
| Characteristic | All Patients (n = 979) |
De Novo (n = 759) | Therapy-Related (n = 115) |
AHD (n = 105) |
|---|---|---|---|---|
| Age at HCT (IQR), years | 55 (42–64) | 53 (40–62) | 57 (48–66) | 63 (56–68) |
| Female gender, n (%) | 454 (46%) | 348 (46%) | 69 (60%) | 37 (35%) |
| WBC count at diagnosis (IQR), G/L | 8 (2–40) | 9 (2–48) | 5 (2–33) | 3 (2–14) |
| Cytogenetic risk (MRC), n (%) | ||||
| Favorable | 72 (8%) | 60 (8%) | 12 (11%) | 0 |
| Intermediate | 659 (70%) | 520 (71%) | 68 (61%) | 71 (72%) |
| Adverse | 213 (23%) | 153 (21%) | 32 (29%) | 28 (28%) |
| Time from last remission to HCT (IQR), days | 98 (69–146) | 104 (72–150) | 96 (69–132) | 72 (53–105) |
| Disease status at HCT, n (%) | ||||
| First remission | 747 (76%) | 551 (73%) | 105 (91%) | 91 (87%) |
| Second remission | 232 (24%) | 208 (27%) | 10 (8.7%) | 14 (13%) |
| MFC MRD status before HCT, n (%) | ||||
| MRD-negative | 788 (80%) | 636 (84%) | 87 (76%) | 65 (62%) |
| MRD-positive | 191 (20%) | 123 (16%) | 28 (24%) | 40 (38%) |
| Recovered peripheral blood counts before HCT, n (%) |
680 (69%) | 544 (72%) | 76 (66%) | 60 (57%) |
| HCT-CI category, n (%) | ||||
| Low | 339 (35%) | 293 (39%) | 8 (7.0%) | 38 (36%) |
| Intermediate | 347 (35%) | 279 (37%) | 29 (25%) | 39 (37%) |
| High | 293 (30%) | 187 (25%) | 78 (68%) | 28 (27%) |
| Stem cell source, n (%) | ||||
| BM | 81 (8%) | 68 (9%) | 8 (7%) | 5 (5%) |
| PBSC | 766 (78%) | 584 (77%) | 91 (79%) | 91 (87%) |
| Cord blood | 132 (13%) | 107 (14%) | 16 (14%) | 9 (9%) |
| HLA matching, n (%) | ||||
| Identical related donor | 227 (23%) | 173 (23%) | 35 (30%) | 19 (18%) |
| Matched unrelated donor | 482 (49%) | 369 (49%) | 56 (49%) | 57 (54%) |
| 1–2 allele mismatch | 101 (10%) | 79 (10%) | 5 (4%) | 17 (16%) |
| Haplo-identical | 37 (4%) | 31 (4%) | 3 (3%) | 3 (3%) |
| Cord blood | 132 (13%) | 107 (14%) | 16 (14%) | 9 (9%) |
| Conditioning regimen intensity, n (%) | ||||
| MAC | 583 (60%) | 483 (64%) | 51 (44%) | 49 (47%) |
| Non-MAC | 396 (40%) | 276 (36%) | 64 (56%) | 56 (53%) |
Abbreviations: BM, bone marrow; ELN, European LeukemiaNet; HCT, hematopoietic cell transplantation; HCT-CI, HCT comorbidity index; HLA, human leukocyte antigen; MAC, myeloablative conditioning; MFC, multiparameter flow cytometry; MRC, U.K. Medical Research Council; MRD, measurable residual disease; PBSC, peripheral blood stem cells; WBC, white blood cell count.